Splash Beverage Group Inc（SBEV）のニュースとイベントSBEVSplash Beverage Group Inc

Splash Beverage Changes Name to Endovia Health Sciences

Splash Beverage Group announced its intention to change its corporate name to Endovia Health Sciences, Inc., effective August 21. At that time, the Company will also adopt a new ticker symbol of "EDVA" and launch EndoviaSciences.com in connection with the rebranding. The name change reflects the Company's strategic transformation from a legacy beverage business into a diversified cannabinoid health sciences platform focused on commercializing pharmaceutical assets, advancing FDA-regulated human and veterinary therapeutics, and developing innovative cannabinoid wellness and beverage products. "This is much more than a name change, it is the culmination of a deliberate strategic transformation," said Brady Cobb, Interim CEO. "Over the past six months, we have methodically repositioned the Company by acquiring differentiated pharmaceutical intellectual property, establishing international commercialization opportunities, expanding into FDA-regulated veterinary therapeutics and assembling an experienced cannabinoid pharmaceutical development team. Endovia Health Sciences reflects both who we are today and the company we intend to become."

Selling Stockholders Plan to Sell Up to 5M Shares

This filing relates to the offer and sale from time to time by the selling stockholders of up to 5M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Splash Beverage Enters Exclusive Global Licensing Agreement with Argent BioPharma for CannEpil

Splash Beverage announced that it has entered into an exclusive global licensing agreement with Argent BioPharma for CannEpil, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy in multiple European countries. As part of the transaction, Splash has secured a $1M strategic investment commitment from C/M Capital Partners to support regulatory advancement, clinical development planning, commercialization initiatives and strategic partnership activities. Splash intends to deploy proceeds from the strategic investment toward advancing FDA-related activities, expanding the existing clinical and real-world evidence package, engaging U.S. epilepsy investigators and identifying a strategic pharmaceutical development partner capable of supporting future U.S.-based clinical trials. Under the terms of the agreement, Splash has acquired exclusive worldwide rights to develop, commercialize, market, distribute, sublicense and sell CannEpil for the treatment of drug-resistant epilepsy, refractory epilepsy, seizure disorders and related neurological conditions. The license encompasses all global territories and includes rights to future product improvements, reformulations and next-generation product developments within the licensed field. In addition to its affiliate's $1M capital infusion described above and as consideration for the transaction, Mercer Street Global Opportunity Fund agreed to forgive approximately $5M of Argent BioPharma indebtedness and Splash agreed to issue to $5.5M of newly issued Splash preferred equity as part of the consideration for the license, aligning stakeholders behind the future development and commercialization of the CannEpil platform. Argent BioPharma is incentivized to continue to participate in the long-term success of the program through a royalty equal to 15% of net revenue generated from worldwide sales of CannEpil. The agreement grants Splash exclusive worldwide commercialization rights for an initial twenty-year term and includes rights to sublicense the technology to strategic pharmaceutical partners